LETTERS TO THE EDITOR

Does lymphoma ‘cure’ rheumatoid arthritis?

Prolonged remission in established rheumatoid arthritis (RA) is extremely rare. During a six year follow up of 458 patients Wolfe and Hawley observed two prolonged remissions of more than 48 months, and concluded that ‘once established, RA tends to remain, interrupted briefly in a small minority of patients by remission of disease.’ However prolonged remissions or cures have been described as secondary to Cushing’s disease and human immunodeficiency virus infection. 1, 2 We have observed a case of cure of RA accompanied by secondary Sjögren’s syndrome.

RA was diagnosed in January 1986, in a 53 year old woman. Retrospective examination of her chart shows the presence of six of seven revised criteria for the diagnosis of RA. 3 Her treatment included intramuscular gold, non-steroid anti-inflammatory drugs, and several intra-articular injections of corticosteroids. Considerable improvement was noted at the end of 1988 and has persisted since with enlargement of the salivary glands and the eyelids. Eyelid ‘fat’ was removed in August 1995 for cosmetic and functional purposes and showed infiltration by a monotonous population of small lymphocytes. There was decreased γ globulinaemia (4.8 g/l, normal value = 6 to 16 g/l) with free monoclonal γ heavy chains representing 75% of total IgG and an additional faint IgG κ band suggestive of a second monoclonal paraprotein. Flow cytometry of blood and bone marrow confirmed the presence of two B cell clones. The eyelid enlargement recurred quickly. Subsequent irradiation relieved the visual fields obstruction and was later succeeded extended to the swollen submandibular regions. Sixteen months after diagnosis, the patient’s condition is stable.

The immunologically active polyclonal γ globulin concentration was 1 g/l (reference value 5.4 to 14.8 g/l), which is lower than in other leukaemias/lymphomas. The levels of IgA (0.38 g/l, reference value 0.65 to 1.48 g/l) and IgM (0.28 g/l, reference value 0.45 to 2.6 g/l) were also low. Lymphocyte count was 1120/μl with 54% of T cells and most of the B cells part of the clonal processes. Fifteen months later the paraprotein levels were stable, the polyclonal IgG have increased to 3 g/l, IgA to 0.55 g/l, IgM to 0.35 g/l and lymphopenia worsened at 800.

We think that the following chain of events occurred in this case: immune disorder, autoimmune disease (RA and secondary Sjögren’s syndrome), malignant B cell neoplasm, secondary immunodeficiency with cure of the RA. The first three steps are well known, the fourth is probably exceptional but this case and others 1, 2 suggest that secondary immunodeficiency should be considered during spontaneous cures of well established RA.

ALAIN DUMAS
JAMES STRAUCHEN
Department of Pathology, Mount Sinai School of Medicine, One Gustave L.Levy Place, New York, NY 10029-6574, USA

Insufficiency fracture of the sacrum revealing a pregnancy associated osteoporosis. First case report

Osteoporosis of pregnancy, usually responsible for spinal or femoral fracture, 1 is rare as is insufficiency fracture of the sacrum, usually occurring in the elderly. 2 Magnetic resonance imaging (MRI) permitted during pregnancy, led us to diagnose an insufficiency fracture of the sacrum revealing a pregnancy associated osteoporosis, never previously reported to the best of our knowledge. Rheumatologists need to be aware of this new cause of pelvic pain during pregnancy.

A 29 year old pregnant (seventh month) woman presented with a spontaneous acute claudication in conjunction with a left hyperalgesic buttock pain. Her past medical history showed: low back pain, since the second month of her pregnancy, relieved by rest and paracetamol; smoking (10 packet years) stopped at the sixth month of pregnancy; one spontaneous miscarriage at six months previous.

Table 1 Biological markers

<table>
<thead>
<tr>
<th>Biological markers</th>
<th>Patient</th>
<th>Normal range for our laboratory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum calcemia</td>
<td>2.46 mmol/l</td>
<td>2.2-2.6</td>
</tr>
<tr>
<td>Serum phosphorus</td>
<td>1.07 mmol/l</td>
<td>0.98-1.3</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>140 U/l</td>
<td>36-120</td>
</tr>
<tr>
<td>Proteidina</td>
<td>70 g/l</td>
<td>65-75</td>
</tr>
<tr>
<td>Creatininaemia</td>
<td>91 μmol/l</td>
<td>45-90</td>
</tr>
<tr>
<td>25 OH vitamin D</td>
<td>4 ng/ml</td>
<td>10-35</td>
</tr>
<tr>
<td>Parathyroid hormone</td>
<td>27 ng/l</td>
<td>10-65</td>
</tr>
<tr>
<td>Glu-protein</td>
<td>5.70 ng/ml</td>
<td>4-9</td>
</tr>
<tr>
<td>Antiphospholipid antibody</td>
<td>negative</td>
<td>4-9</td>
</tr>
<tr>
<td>Blood count</td>
<td>normal</td>
<td>normal</td>
</tr>
<tr>
<td>CRP</td>
<td>5 mg/l</td>
<td>0-10</td>
</tr>
<tr>
<td>ESR</td>
<td>21 mm/1st h</td>
<td>5-15</td>
</tr>
<tr>
<td>Thyroid hormone</td>
<td>normal</td>
<td>normal</td>
</tr>
</tbody>
</table>

CRP=C reactive protein, ESR=erythrocyte sedimentation rate.

Figure 1 Magnetic resonance imaging of the pelvis showing on the left part of the sacrum a high signal intensity on T2 weighted sequences. 3

No endotoxin detected in plasma of patients with ankylosing spondylitis

Endotoxin has long been known to be an important virulence factor for Gram negative bacteria. It is chemically classified as lipopolysaccharide (LPS) and it is one of the major constituents of the outer membrane of Gram negative bacteria. This molecule is also known to be responsible for many injurious effects of Gram negative bacterial infections and thus is clinically important.1

The pathogenesis of ankylosing spondylitis (AS) is still unknown. A microbial aetiology has been suggested as a causal factor.2 Sudden unforeseen accelerated fracture of the sacrum in association with pregnancy has been previously reported in 28 of 184 women undergoing pregnancy.3-5

Our case is original because both the localisation and the aetiology of the fracture are unusual. To the best of our knowledge, no spontaneous fracture of the sacrum during pregnancy had previously been reported in the medical literature. Calcium disorders may occur during pregnancy; this patient’s previous bone status was unknown. The increase in alkaline phosphatase activity could be attributed both to a physiological rise in pregnancy and to vitamin D deficiency. In this case the fracture might have occurred in relation with the vitamin D deficiency (possibly in relation with seasonal variation in winter time and bed rest), a mechanical mechanism (fetus weight, as the fracture occurred during the last trimester), and a metabolic mechanism, related to a long term heparin therapy (> 4 months). Heparin may have been a relevant risk factor, because any other risk factor (malignancy, excess alcohol, systemic lupus erythematosus), would have been detected. The heparin osteopenic effect, probably related to a direct effect on osteoclast development and activity, has been demonstrated during pregnancy with dose related calcium homeostasis disorders induced by heparin, although fractures may occur during low dose, short-term prophylaxis.6,7 Sudden fracture during pregnancy may be an underestimated occurrence, because of the lack of specificity of the symptoms and because x-ray imaging is not possible. Magnetic resonance imaging should be considered instead of radiographs during pregnancy when clinical features suggest sacrum fracture.

VERONIQUE BREUIL
OLIVIER BROCCI
LIANA EULLER-ZIEGLER
Rheumatology Department

ANNE GRIMAUD
Radiology Department, "Arche University, Nice 06200, France

Correspondence to : L. Euller-Ziegler.


However, the same assay was used by Wagenner et al., who found increased plasma endotoxin concentrations in one third of the AS patients and in up to half of the patients with sacroiliitis and peripheral arthritis or rheumatoid arthritis. In their study the blood sampling and handling was not reported. The Limulus assay is known to be extremely sensitive to contaminants.

In conclusion, this study we could not confirm the reported findings on increased plasma endotoxin concentrations in patients with AS. However, this does not exclude the concept that endotoxin or LPS may play an important part in the pathogenesis of AS.

O MAKI-IKOLA
J MERTSOLA
K GRANFORS
National Public Health Institute, Turku, Finland

P KLUSELA
The Haartman Institute, Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland

K LEHTINEN
R VON ESSIN
Rheumatism Foundation Hospital, Heinola, Finland

H SAXEN
Children’s Hospital, University of Helsinki, Helsinki, Finland

Correspondence to : Dr O Mäki-Ikola, National Public Health Institute, Department in Turku, Kävijäntie 13, FIN-20520 Turku, Finland.

Treatment with etidronate for men with idiopathic osteoporosis

In a recent overview of current and potential future drug treatments for osteoporosis, the therapies for osteoporosis in men were discussed briefly.1 Osteoporosis in men is a heterogeneous disease of which 50% of the cases are classified as idiopathic osteoporosis (IOP).1

Long term data on treatment of men with IOP are not yet available.

In an uncontrolled open study of 22 white men with IOP, we have studied prospectively, the effect of a two year treatment with cyclic etidronate (400 mg/d during two weeks every three months) and calcium (500 mg/d during 10 weeks every three months). All patients were extensively screened to exclude any causes of secondary osteoporosis, such as hypogonadism and hypercalciuria, or any other risk factors. Liver function tests were normal in all patients and there was no excessive alcohol consumption either. Bone mineral density (BMD) measurements were performed every six months in the lumbar spine (L2-L4) and in the femoral neck, using dual energy x ray absorptiometry. Precision was <1% in the spine and <2% in the femoral neck. Results were expressed as mean (SEM). Percent changes from baseline were analysed by a paired t test. Patients with vertebral fractures or a T score of < −2 in the lumbar spine, or both were included (a T score of 1 being the number of standard deviations from the mean bone density of young healthy controls). Mean (SD) age of the patients was 56 (2) years. Seventeen patients showed fractures of vertebrae (one fracture in seven patients and ≥ two in 10 patients) and 11 patients of the appendicular skeleton (one fracture in eight patients and ≥ two in three patients).

Mean T score was −3.2 (0.3) (range −5.4 to −0.5) in the spine and −2.8 (0.2) (range −5.0 to −0.5) in the femoral neck. After two years of treatment with cyclic etidronate, intention to treat analysis indicated an increase in BMD of +7.3 (1.1)% in the spine (p<0.001) and of +2.4 (1.2)% in the hip (p<0.05) (fig 1). The increase of BMD in the spine was similar if patients with spinal fractures (n=8) were excluded (+7.9 (2.0), p<0.01).

The significant increase of BMD in the spine during cyclic etidronate therapy is comparable to the treatment effect in postmenopausal osteoporosis.2 This is the first study to indicate that cyclic etidronate can significantly increase BMD in the hip of men with IOP and substantial bone loss.

This study suggests that cyclic etidronate may be valuable in men with IOP, although double blind controlled prospective studies, with long term follow up are necessary to adequately assess this. In addition, whether cyclic etidronate will beneficially influence fracture rates in men will probably remain unknown, as large groups of patients are required to study this effect and as osteoporosis is less frequent in men than in women.

Finger drop in a patient with rheumatoid arthritis

I wish to comment on the case report by McDonald and Smith.1 Although the authors report that a tomographic arthrogram showed no cystic extension of the joint capsule, the two figures are almost identical with those previously seen in antecubital cysts in rheumatoid arthritis.2 These ‘cysts’ are corollaries to the popliteal cysts and are generally missed in physical examinations because the bulge they produce often disappears into the fleshy part of the forearm. Clearly, they represent an escape for the effusion in a joint distended by severe synovitis and its products. The proximity of major nerves puts them at risk, as reported by McDonald and Smith.

GEORGE E EHRLICH
One Independence Place - 1
241 South Sixth Street
Philadelphia, Pennsylvania 19106-3731, USA

Authors’ reply

We thank Dr Ehrlich for his interest in our case report of a patient with a posterior interosseous nerve lesion, secondary to rheumatoid arthritis with synovitis of the elbow joint.1 We were not aware of his paper describing antecubital cysts in rheumatoid arthritis but, as our case was mainly an illustration of an unusual compressive neuropathy rather than a description of synovial cysts of the elbow joint, we would not have included the topic of his paper in our literature search. We agree that there is a similarity between the arthrograms in Dr Ehrlich’s paper and that illustrated in our paper. Our case reinforces the conclusions of Dr Ehrlich’s paper 23 years ago that antecubital cysts are relatively common, are frequently overlooked, and should be actively sought when a patient with rheumatoid arthritis presents with symptoms suggestive of a compressive neuropathy in the forearm. We hope that our case report and Dr Ehrlich’s letter will remind rheumatologists to consider this potentially treatable cause of upper limb disability in patients with rheumatoid arthritis.

M D SMITH
S P MCDONALD
Department of Medicine,
Flinders Medical Centre,
South Road, Bedford Park,
South Australia 5042


No endotoxin detected in plasma of patients with ankylosing spondylitis

O MÄKI-IKOLA, J MERTSOLA, K GRANFORS, P KUUSELA, K LEHTINEN, R VON ESSEN and H SAXEN

Ann Rheum Dis 1997 56: 279
doi: 10.1136/ard.56.4.279